Ablation Devices Market Size, Share, Growth Analysis, By Ablation Devices Market(Radiofrequency Devices, Laser/Light Ablators (Excimer laser ablators, Cold laser ablators), Ultrasound Devices (High-intensity focused ultrasound ablators), By Application(Cardiovascular Disease Treatment, Cosmetic/Aesthetic Surgery, Orthopaedic Treatment, Cancer Treatment (Liver Cancer), By End use(Hospitals, Surgical Centers, Ablation Centers, Ambulatory Surgical Centers), By Region - Industry Forecast 2024-2031

The ablation devices market is expanding steadily as the prevalence of heart illnesses such as atrial fibrillation (AF), atrial flutter, and cardiac arrhythmias rises. As a result, various mid-to-large-sized companies have increased their R&D efforts in this industry. Furthermore, even smaller companies have altered their focus and increased their R&D operations, resulting in a rise in product development (approvals & launches), and thereby contributing to the expansion of the ablation devices sector. In April 2016, Medtronic introduced the new Barrx 360 Express radiofrequency ablation balloon catheter, which is a self-adjusting circumferential RFA catheter used to eliminate damaged tissues. This catheter is expected to help with the treatment of Barrett's esophagus.

Ablation Devices Market Top Player’s Company Profiles

• Johnson & Johnson (US) 
• Medtronic (Ireland) 
• Boston Scientific Corporation (US) 
• Abbott (US) 
• AtriCure, Inc. (US) 
• AngioDynamics (US) 
• ConMed Corporation (US) 
• Olympus Corporation (Japan) 
• Smith+Nephew (UK) 
• Stryker (US) 
• Cynosure Lutronic (US) 
• BioVentus (US) 
• Merit Medical Systems (US) 
• Canyon Medical Inc. (US) 
• Arthrex, Inc. (US) 
• IceCure Medical (Israel) 
• Minimax Medical Holding Group (China) 
• CardioFocus (US) 
• EDAP TMS (France) 
• Mermaid Medical (Denmark) 
• Monteris (Canada) 
• SonaBlate Corp. (US) 
• Eco Medical (US) 
• Surgnova (France) 

Ablation Devices Market Recent Development

• In May 2024, Clarivate Identifies Five Breakthrough Medical Technologies Set to Transform Patient Care in 2024. 
• In May 2024, FDA issues 510(k) clearance for US Medical Innovations’ ablation system. 
• In May 2024, The Apple Watch can now be used in clinical studies for atrial fibrillation. In an industry first, FDA certified the atrial fibrillation history feature on the Apple Watch for clinical studies under the medical device development tools (MDDT) program – the first digital health technology to achieve such status. 
• In October 2023, Boston Scientific unveiled the LUX-Dx II+ Insertable Cardiac Monitor (ICM) System, representing a next-generation solution for long-term monitoring of arrhythmias linked to conditions such as atrial fibrillation (AF), cryptogenic stroke, and syncope.  
• In October 2023, STARmed Co., Ltd., a prominent South Korean medical device company, inaugurated its U.S. subsidiary, STARmed America, on October 1st, 2023. This strategic initiative highlights STARmed's dedication to enhancing patient care in North America, aligning with its broader vision for global expansion.  
• In September 2022, CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, and Focalyx Technologies, a developer of image-guided fusion target devices, announced that they will exhibit and demonstrate their respective TRANBERGTM Thermal Therapy System for focal laser ablation and Focalyx Fusion medical device at the FOCAL 2022 Conference in Los Angeles, September 22-24, 2022. "Frontiers in Oncologic Prostate Care and Ablative Local Therapy" is the conference theme.